Galy A. auteur aut IRD Ciaffi L. auteur aut IRD Le Moing V. auteur aut IRD Eymard-Duvernay Sabrina auteur aut IRD Abessolo H. auteur aut IRD Toby R. auteur aut IRD Ayangma L. auteur aut IRD Le Gac S. auteur aut IRD Mpoudi-Etame M. auteur aut IRD Koulla-Shiro S. auteur aut IRD Delaporte Eric auteur aut IRD Cournil Amandine auteur aut IRD text journalArticle eng text/pdf reformatted digital access Background: Since antiretroviral therapy (ART), HIV-infected individuals experience mainly non-AIDS-related conditions, among which infectious events are prominent. We aimed to estimate incidence and describe overall spectrum of infectious events, including all grade events, among HIV-1-infected adults failing first-line ART in Yaounde, Cameroon. Methods: All patients from Cameroon enrolled in the second-line ART 2LADY trial (ANRS12169) were included in this secondary analysis. Medical files were reviewed with predefined criteria for diagnosis assessment. Incidence rates (IR) were estimated per 100 person-years (% PY). Results: A total of 302 adult patients contributing 840 PY experienced 596 infectious events (IR 71% PY). Only 29 (5%) events were graded as severe. Most frequent infections were upper respiratory tract infections (15% PY), diarrhoea (9% PY) and malaria (9% PY). A total of 369 (62%) infections occurred during the first year (IR 130% PY) followed by a persistent lower incidence during the following 3 years. Higher IR were observed in patients with CD4(+) T-cell count < 200 cells/mm(3) for all infectious events except for mycobacterial and parasitic infections. IR of viral, bacterial and parasitic infectious events were lower in case of co-trimoxazole use in patients with CD4(+) T-cell count < 200 cells/mm(3). Conclusions: Infectious events are common and mainly occur during the first year after treatment initiation. Second-line ART initiation had a positive impact on the entire spectrum of infectious morbidity. specialized CAMEROUN YAOUNDE 052 050 21 6 547-552 2016 1359-6535 https://www.documentation.ird.fr/hor/fdi:010081630 10.3851/imp3030 1359-6535 [F B010081630] https://www.documentation.ird.fr/hor/fdi:010081630 https://horizon.documentation.ird.fr/exl-doc/pleins_textes/divers21-03/010081630.pdf IRD - Base Horizon / Pleins textes 2017-05-09 2025-02-27 fdi:010081630 fre